InfuSystem Holdings, Inc. (INFU)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 97 | 102 | 110 | 126 | 135 | 143 | 143 | 145 |
| Operating profit | $m | 12 | 13 | ||||||
| Net profit | $m | 17 | 1 | 0 | 1 | 2 | 7 | 9 | 10 |
| EPS reported | $ | 0.31 | 0.41 | ||||||
| Operating cashflow per share | $ | 1.18 | 1.16 | ||||||
| Capex per share | $ | 0.42 | 0.21 | ||||||
| FCF per share | $ | 0.76 | 0.95 | ||||||
| Free cash flow | $m | 16 | 19 | ||||||
| Net debt | $m | 0 | 19 | ||||||
| Book value equity | $m | 57 | 59 | ||||||
| Book value per share | $ | 2.72 | 2.83 | ||||||
| Number of shares | m | 21.1 | 20.93 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 28.94 | 31.75 | ||||||
| P/B LTM | x | 3.23 | 3.13 | ||||||
| P/S LTM | x | 1.29 | 1.29 | ||||||
| P/FCF LTM | x | 11.79 | 9.70 | ||||||
| EV/EBITDA LTM | x | 7.36 | 8.13 | ||||||
| EV/Sales LTM | x | 1.29 | 1.88 | ||||||
| Earnings Yield LTM | % | +3.46% | +3.15% | ||||||
| FCF Yield | % | +8.48% | +10.30% | ||||||
| Quality | |||||||||
| ROE | % | +11.56% | +14.81% | ||||||
| ROIC | % | +9.25% | +11.26% | ||||||
| Operating margin | % | +8.31% | +9.26% | ||||||
| Gross margin | % | +55.98% | +57.45% | ||||||
| FCF/Sales | % | +10.96% | +13.32% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +181.82% | +272.73% | ||||||
| Sales Growth YoY | % | +6.36% | +6.28% | ||||||
| Net Income Growth YoY | % | +182.60% | +264.31% | ||||||
| FCF Growth | % | +498.71% | +627.11% | ||||||
| Operating Profit Growth | % | +72.98% | +92.53% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 4.59 | 0.82 | ||||||
| Net Debt/EBITDA | x | 0.01 | 0.98 | ||||||
| EBIT/Net interest | x | 9.18 | 18.38 | ||||||
| Net debt/market cap | % | +1.85% | +8.25% | ||||||
| Net debt/Equity | x | 0.00 | 0.33 | ||||||
| Gross debt/equity | x | 0.06 | 0.39 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free